1.19
1.19 (0%)
As of Apr 17, 2025
Fibrobiologics, Inc [FBLG]
Source:
Company Overview
Fibrobiologics, Inc is a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal.
| Country | United States |
| Headquarters | houston, texas |
| Phone Number | (281) 651-5150 |
| Industry | manufacturing |
| CEO | Pete O’Heeron |
| Website | ir.fibrobiologics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-13.7 |
| Net Income | $-11.2 |
| Net Cash | $4.8 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -79% |
| Profit as % of Stockholder Equity | -408.1% |
Management Effectiveness
| Return on Equity | -408.1% |
| Return on Assets | -67.9% |
| Turnover Ratio | |
| EBITA | $-13.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $16.4 |
| Total Liabilities | $13.7 |
| Operating Cash Flow | $-11.9 |
| Investing Cash Flow | $-0.2 |
| Financing Cash Flow | $16.9 |
